The Sobel blog

Regulation, read as a business decision

Technical analysis of ANVISA, EU MDR and IVDR, FDA, MHRA and Health Canada, and what each change means for your timeline, costs and market strategy.

Maik Endler Curated byMaik EndlerFounder & CEO, Sobel

Your briefing

Pick your product, your market, or both.

I work with

and I want to sell in

    All segmentsBrazilGuides

    Product rejected by ANVISA: what now?

    A rejection is not the end of your product in Brazil. See the two paths, the 30-day appeal deadline and what to do before…

    Maik Endler · · 6 min read

    All segmentsBrazilGuides

    The dossier errors that stall ANVISA applications most

    Most stalled dossiers have formal or consistency gaps, not serious errors. The five families of errors and how to keep your dossier from coming…

    Maik Endler · · 4 min read

    All segmentsBrazilNews

    News: Anvisa Regulatory Sandbox and Global Updates

    Anvisa advances its Regulatory Sandbox initiative for personalized cosmetics while global regulators strengthen post-market surveillance.

    Maik Endler · · 3 min read

    Medical devicesUSANews

    News: FDA and AI-Powered Medical Devices

    Learn more about the FDA’s regulatory framework for AI-powered medical devices and other global recent updates.

    Maik Endler · · 3 min read

    Medical devicesUSANews

    News: FDA Publishes Q3E for Extractables & Leachables

    The FDA has published a new guideline aligned with ICH Q3E to support the assessment of Extractables & Leachables (E&L), along with supporting documentation…

    Maik Endler · · 3 min read

    Medical devicesGlobalNews

    News: What is MDSAP? Malaysia Joins the Program

    Malaysia joins MDSAP, expanding global audits. Plus: FDA software guidance, IMDRF PCCP guideline, and Anvisa’s new import process.

    Maik Endler · · 4 min read

    Newsletter

    Subscribe to our newsletter to receive the latest updates and insights.

    You may unsubscribe at any time using the link in our newsletter.